title: Sialyl Lewis X-polysaccharide conjugates: targeting inflammatory lesions.
abstract: A novel system for active targeting of inflammatory lesions has been established. A SLeX-CMPul conjugate (2) showed accumulation that was 2.5-fold higher in inflammatory lesions in vivo than a SLN-CMPul conjugate (4) and 300-fold higher than monovalent SLeX (6).
authors.affiliation: Drug Delivery System Institute, Ltd., Chiba, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Sakagami
authors.forename: K
authors.initials: K
authors.lastname: Horie
authors.forename: K
authors.initials: K
authors.lastname: Nakamoto
authors.forename: T
authors.initials: T
authors.lastname: Kawaguchi
authors.forename: H
authors.initials: H
authors.lastname: Hamana
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology*; D002240:Carbohydrate Sequence; D004337:Drug Carriers; D004487:Edema / Q000188:drug therapy; D007249:Inflammation / Q000188:drug therapy; D051379:Mice; D008969:Molecular Sequence Data; D009844:Oligosaccharides / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology*; D011134:Polysaccharides / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology*; D000080506:Sialyl Lewis X Antigen
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004337:Drug Carriers; D009844:Oligosaccharides; D011134:Polysaccharides; D000080506:Sialyl Lewis X Antigen